{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:33:05Z","timestamp":1786548785511,"version":"build-2736575974"},"reference-count":39,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Childhood Obesity"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine changes in weight status after initiating zonisamide in children with epilepsy and elevated body mass index (BMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>Retrospective chart review of children aged 2 to \u226418 years with epilepsy treated with zonisamide, assessing BMI changes over 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 140 children were included; mean age (SD) at initiation was 9.60 years (3.93). BMI categories included 28 children with severe obesity, 28 with mild\u2013moderate obesity, 28 with overweight, and 56 with healthy weight. Participants were 56.6% female, 91.4% non-Hispanic\/Latino, and 88.6% White. At 2 years, BMI\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      score decreased significantly across all BMI groups: severe obesity \u22120.38 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 13, 95% CI \u22120.64 to \u22120.13;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.003), mild-moderate obesity \u22120.39 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 15, 95% CI \u22120.62 to \u22120.16;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.001), overweight \u22120.60 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 14, 95% CI \u22120.84 to \u22120.36;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), and healthy weight \u22120.46 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 21, 95% CI \u22120.63 to \u22120.28;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Significant BMI\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      score reductions were also observed across age groups: 2\u201310 years \u22120.48 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 40, 95% CI \u22120.62 to \u22120.34), &gt;10\u201313 years \u22120.27 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 15, 95% CI \u22120.50 to \u22120.04), and \u226513 years \u22120.63 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 12, 95% CI 0.89 to \u22120.36).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>BMI reduction persisted up to 2 years following zonisamide initiation in children with epilepsy. Further prospective studies are needed to evaluate the weight loss effect and safety of zonisamide in children with epilepsy and elevated BMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21532176261461791","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:07:47Z","timestamp":1782558467000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Weight Changes in Children and Adolescents with Epilepsy and Overweight\/Obesity Treated with Zonisamide"],"prefix":"10.1177","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7451-1503","authenticated-orcid":false,"given":"Mostafa","family":"Salama","sequence":"first","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie","family":"Touma","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doha","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wong-Kisiel","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesina","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"7","key":"e_1_3_4_2_1","doi-asserted-by":"crossref","first-page":"e2521170","DOI":"10.1001\/jamanetworkopen.2025.21170","article-title":"Prevalence of extremely severe obesity and metabolic dysfunction among US Children and Adolescents","volume":"8","author":"Munte E","year":"2025","unstructured":"1.Munte E, , Zhang X, , Khurana A, , Hartmann P. Prevalence of extremely severe obesity and metabolic dysfunction among US Children and Adolescents. JAMA Netw Open 2025;8(7):e2521170.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.15585\/mmwr.mm7341a5","article-title":"Prevalence of obesity and severe obesity among persons aged 2\u201319 years \u2014 United States, 1999\u20132000 Through 2021\u20132023","volume":"73","author":"QuickStats","year":"2024","unstructured":"2.QuickStats. Prevalence of obesity and severe obesity among persons aged 2\u201319 years \u2014 United States, 1999\u20132000 Through 2021\u20132023. MMWR Morb Mortal Wkly Rep 2024;73:936.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad361"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738231203761"},{"issue":"17","key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.0000000000002611","article-title":"Obesity and overweight as CAE comorbidities and differential drug response modifiers","volume":"86","author":"Arya R","year":"2016","unstructured":"5.Arya R, , Gillespie CW, , Cnaan A, , Childhood Absence Epilepsy Study Group et al.;. Obesity and overweight as CAE comorbidities and differential drug response modifiers. Neurology 2016;86(17):1613\u20131621.","journal-title":"Neurology"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ab2b11"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306175"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.897333"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(02)00505-2"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1371"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12233"},{"issue":"4","key":"e_1_3_4_13_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/epi.12548","article-title":"Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: Results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial","volume":"55","author":"Guerrini R","year":"2014","unstructured":"12.Guerrini R, , Rosati A, , Bradshaw K, , Giorgi L. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: Results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55(4):568\u2013578.","journal-title":"Epilepsia"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.14.1820"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.99"},{"issue":"12","key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.4088\/JCP.v67n1209","article-title":"Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial","volume":"67","author":"McElroy SL","year":"2006","unstructured":"15.McElroy SL, , Kotwal R, , Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial. J Clin Psychiatry 2006;67(12):1897\u20131906.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v65n0108","article-title":"Zonisamide in the treatment of binge-eating disorder: An open-label, prospective trial","volume":"65","author":"McElroy SL","year":"2004","unstructured":"16.McElroy SL, , Kotwal R, , Hudson JI, et al. Zonisamide in the treatment of binge-eating disorder: An open-label, prospective trial. J Clin Psychiatry 2004;65(1):50\u201356.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.07.007"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.01.004"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153380"},{"issue":"6","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly AS","year":"2022","unstructured":"20.Kelly AS, , Bensignor MO, , Hsia DS, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid 2022;1(6).","journal-title":"NEJM Evid"},{"issue":"1","key":"e_1_3_4_22_1","doi-asserted-by":"crossref","first-page":"bvaf179","DOI":"10.1210\/jendso\/bvaf179","article-title":"Effect of topiramate on weight status in young children with severe obesity","volume":"10","author":"Salama M","year":"2026","unstructured":"21.Salama M, , Hassan D, , Pittock S, et al. Effect of topiramate on weight status in young children with severe obesity. J Endocr Soc 2026;10(1):bvaf179.","journal-title":"J Endocr Soc"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2022.0062"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814542481"},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"1369270","DOI":"10.3389\/fendo.2024.1369270","article-title":"Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting","volume":"15","author":"Bomberg EM","year":"2024","unstructured":"24.Bomberg EM, , Clark J, , Rudser KD, et al. Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting. Front Endocrinol (Lausanne) 2024;15:1369270.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.02.023"},{"issue":"5","key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ane.12373","article-title":"Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy","volume":"131","author":"Lagae L","year":"2015","unstructured":"26.Lagae L, , Meshram C, , Giorgi L, , Patten A. Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. Acta Neurol Scand 2015;131(5):341\u2013346.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"e_1_3_4_28_1","first-page":"311","article-title":"Zonisamide for weight loss in adolescents","volume":"18","author":"Nguyen ML","year":"2013","unstructured":"27.Nguyen ML, , Pirzada MH, , Shapiro MA. Zonisamide for weight loss in adolescents. J Pediatr Pharmacol Ther 2013;18(4):311\u2013314.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.03.039"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21782"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3459"},{"key":"e_1_3_4_32_1","unstructured":"31.CDC. CDC Growth Charts. CDC; 2024. Available from: https:\/\/www.cdc.gov\/growthcharts\/cdc-growth-charts.htm"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"issue":"10","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.57.10.1774","article-title":"Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures","volume":"57","author":"Faught E","year":"2001","unstructured":"33.Faught E, , Ayala R, , Montouris GG, , Leppik IE, , Zonisamide 922 Trial G. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57(10):1774\u20131779.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_4_35_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0404.2008.01119.x","article-title":"The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy","volume":"119","author":"Wellmer J","year":"2009","unstructured":"34.Wellmer J, , Wellmer S, , Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009;119(4):233\u2013238.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton V","year":"2007","unstructured":"35.Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30(4):230\u2013240.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2009.02.065","article-title":"Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors","volume":"454","author":"Yamamura S","year":"2009","unstructured":"36.Yamamura S, , Saito H, , Suzuki N, et al. Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors. Neurosci Lett 2009;454(1):91\u201396.","journal-title":"Neurosci Lett"},{"issue":"8","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2016-1885","article-title":"Which amount of BMI-SDS reduction is necessary to improve cardiovascular risk factors in overweight children","volume":"101","author":"Reinehr T","year":"2016","unstructured":"37.Reinehr T, , Lass N, , Toschke C, et al. Which amount of BMI-SDS reduction is necessary to improve cardiovascular risk factors in overweight children? J Clin Endocrinol Metab 2016;101(8):3171\u20133179.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.12.049"},{"issue":"8","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/dom.12275","article-title":"Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment","volume":"16","author":"Shin JH","year":"2014","unstructured":"39.Shin JH, , Gadde KM, , Ostbye T, , Bray GA. Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment. Diabetes Obes Metab 2014;16(8):766\u2013768.","journal-title":"Diabetes Obes Metab"}],"container-title":["Childhood Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176261461791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21532176261461791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176261461791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:32:02Z","timestamp":1786545122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21532176261461791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1177\/21532176261461791"],"URL":"https:\/\/doi.org\/10.1177\/21532176261461791","relation":{},"ISSN":["2153-2168","2153-2176"],"issn-type":[{"value":"2153-2168","type":"print"},{"value":"2153-2176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}